The Boston Globe names Cubist to Globe 100`s Top Places to Work `09

Top-ranked life sciences company
LEXINGTON, Mass.--(Business Wire)--
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has been
named one of the Top Places to Work in Massachusetts in the second annual
employee-based survey from The Boston Globe. The Globe 100`s Top Places to Work
`09 magazine was published in the Sunday Globe on November 8th. Online, the
report can be found at www.boston.com/topworkplaces. Cubist was ranked 37th on
the overall list and is the top-ranked life sciences company on the list. Cubist
also appeared on last year`s inaugural list.

Produced by the same team that compiles the 22-year-old Globe 100 report of the
best-performing public companies in Massachusetts, where Cubist ranked number
one earlier this year, the Top Places to Work recognizes the most progressive
companies in the state based on employee opinions about company leadership,
compensation and training, diversity/inclusion, career development,
family-friendly flexibility, and values and ethics. Private companies and
nonprofits as well as publicly-held businesses were included in the analysis.

The rankings in the Globe 100`s Top Places to Work are based on survey
information collected by Workplace Dynamics, an independent company specializing
in employee engagement and retention, from 86,000 employees at 269 Massachusetts
organizations. This marks the second year that a Globe 100 report has honored
private as well as publicly-held organizations.

Cubist President and CEO Michael Bonney said, "This recognition from the Boston
Globe reaffirms what all of us at Cubist feel every day - this is a great place
to work! Our employees are committed to building the world`s leading company
focused on providing therapies for acutely ill patients. To ensure that
mission`s success, we depend on retaining and attracting the best and most
highly motivated and committed scientific and business talent. Creating a
positive work environment helps us achieve that end."

Steve Ainsley, the publisher of The Boston Globe, stated, "The companies
included in the Globe 100`s Top Places to Work have succeeded in creating a
positive workplace for their employees in the midst of the uncertainties of the
general economy. I congratulate each of them for an outstanding accomplishment."

To qualify for the Globe 100`s Top Places to Work, a company must have more than
100 employees in Massachusetts. Nearly 600 qualified companies accepted an
invitation to participate. Rankings were based on composite scores calculated
purely on the basis of employee responses.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
research, development, and commercialization of pharmaceutical products that
address unmet medical needs in the acute care environment. In the U.S., Cubist
markets CUBICIN (daptomycin for injection), the first antibiotic in a new class
of anti-infectives called lipopeptides. In July 2008, Cubist entered into an
agreement with AstraZeneca to promote their established antibiotic, MERREM I.V.
(meropenem for injection) in the U.S. The Cubist product pipeline includes
ecallantide, a recombinant human protein in Phase 2 clinical trials - CONSERV-1
and CONSERV-2 - for the reduction of blood loss during cardiac surgery, and two
Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium
difficile-associated diarrhea) and the other in multi-drug resistant (MDR)
Gram-negative infections. In addition, the Company, in collaboration with
Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND program underway in
novel treatments for respiratory syncytial virus (RSV) infections in children
using Alnylam`s RNA-interference (RNAi) technology. The RSV program also
includes ALN-RSV01, for which Cubist has opt-in rights after Alnylam completes a
Phase 2b study of ALN-RSV01 for the treatment of RSV infection in adult lung
transplant patients. Cubist is headquartered in Lexington, MA. Additional
information can be found at Cubist`s web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of
companies.

Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Senior Director, Corporate Communications
eileen.mcintyre@cubist.com
or
Weber Shandwick
Tara Murphy, 617-520-7045
tara.murphy@webershandwick.com

Copyright Business Wire 2009